
ANTI-SEIZURE MEDICATION

If you think a patient should be maintained on a specific manufacturer's product, prescribe either by specifying brand name or by using the generic drug name and name of the manufacturer. ¹



Below are the brand leader or originator of the currently licensed anti-seizure medication for treating epilepsy in children and adults and alternative formulations available for those unable to swallow tablet or capsules. The size and shape of tablets and capsules can impact on a patient's ability to swallow them.

The photos and measurements of the tablets and capsules are there to aid formulation choice. Please note that generic versions of these products are available for most actives, but they may differ in size and shape.

The photos and measurements of the tablets and capsules are there to aid formulation choice. Please note that generic versions of these products are available for most actives, but they may differ in size and shape. CATEGORY 3¹ For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer's product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors. BRIVARACETAM Briviact Tablets 10mg 25mg 50mg 75mg 100mg 100mg

Emeside Generic Capsules

GABAPENTIN

Neurontin Tablets

LACOSAMIDE

Acetazolamide Powder

12.5mg, 25mg, 50mg,

100mg, 150mg & 200mg

for Injection

Cannabidio

Oral Solution

Diazepam

Oral Solution

Oral Suspension

Rectal Solution

Formulations that may help patients who struggle to swallow tablets/capsules:






Stiripentol Capsules

100mg, 250mg & 500mg

Stiripentol Powder for

Oral Suspension

250mg & 500mg



Fenfluramine

Oral Solution

Oromucosal Solution

2.5mg, 5mg, 7.5mg & 10mg

Fosphenytoin Sodium

Concentrate for

Infusion/Injection

Gabitril Tablets



Supporting healthcare professionals, patients and their families and carers through educational resources

This poster was last updated on 1st November 2023

HAVE YOU GOT THE LATEST VERSION?

Please use the QR code to check that this

is the latest version of the poster.

WE KNOW ...

That for anti-seizure medications (ASMs), the choice of active ingredient is important... ... but so is the formulation.

WHICH MEANS ...

- For new ASM initiations, there should be an informed decision made on the best formulation of the chosen active ingredient in order to optimise the outcomes for that patient.
- Not all formulations contain the same excipients. Excipients are particularly important for children, for example products may contain alcohol, colouring agents or preservatives. See Swallowingdifficulties.com below for more information.
- For continuity of care, the specialist's choice of formulation should be adhered to on renewing and fulfilling the prescription.
- On reviewing patients if they are not seizure free consideration should be given to whether they are on the optimal formulation of that active ingredient to optimise their outcomes.






epilepsy society

Transforming the lives of people with epilepsy through world-leading research, advocacy and care.

www.epilepsysociety.org.uk

FORMULATION KEY





The development of this poster was funded by Desitin Pharma.

We would like to thank Day Lewis for their support in the photography of the medicines.

DIC: UK/CP/0606 **DOP:** November 2023 (All information is correct as of the time of producing this poster – November 2023)